Roche Holding Ltd. (ROG) Given a CHF 325 Price Target by Goldman Sachs Group, Inc. (The) Analysts
Goldman Sachs Group, Inc. (The) set a CHF 325 price target on Roche Holding Ltd. (VTX:ROG) in a research note released on Monday. The brokerage currently has a buy rating on the healthcare company’s stock.
ROG has been the subject of a number of other research reports. HSBC Holdings plc set a CHF 215 price objective on Roche Holding and gave the company a sell rating in a research report on Tuesday, July 11th. Jefferies Group LLC set a CHF 305 price objective on Roche Holding and gave the company a buy rating in a research report on Monday, May 29th. Kepler Capital Markets set a CHF 231 price objective on Roche Holding and gave the company a neutral rating in a research report on Tuesday, June 6th. Deutsche Bank AG set a CHF 273 price objective on Roche Holding and gave the company a buy rating in a research report on Tuesday, June 27th. Finally, BNP Paribas set a CHF 250 price objective on Roche Holding and gave the company a neutral rating in a research report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of CHF 267.53.
Roche Holding (VTX:ROG) opened at 244.00 on Monday. Roche Holding has a 52-week low of CHK 218.30 and a 52-week high of CHK 273.00. The firm’s 50-day moving average price is CHK 243.56 and its 200 day moving average price is CHK 252.42. The stock has a market cap of CHK 208.20 billion and a P/E ratio of 21.66.
TRADEMARK VIOLATION NOTICE: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/14/roche-holding-ltd-rog-given-a-chf-325-price-target-by-goldman-sachs-group-inc-the-analysts.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.